Objective To explore the effect of Docetaxel combined with Carboplatin in the treatment of ovarian cancer and its influence on immune status and blood flow parameters.Methods A total of 68 patients with advanced ovarian cancer treated in Yangjiang People′s Hospital from January 2018 to January 2020 were selected as the research objects and divided into the observation group (35 cases) and the control group (33 cases) according to the treatment plan, the observation group was treated with Docetaxel combined with Carboplatin, the control group was treated with Paclitaxel combined with Cisplatin.The efficacy, immune indexes, blood flow parameters, median survival time and adverse reactions of the two groups were compared.Results There was no statistically significant difference in the efficacy between the two groups (P＞0.05).After treatment, CD3+, CD4+ in the observation group were higher than those in the control group, and the differences were statistically significant (P＜0.05).After treatment, the maximum systolic flow velocity(PSV) of the observation group was lower than that of the control group, while the vascular resistance index (RI) and pulse index (PI) of the observation group were higher than those of the control group, and the differences were statistically significant (P＜0.05).There were no statistically significant differences in the median survival time and the incidence of adverse reactions between the two groups (P＞0.05).Conclusion Docetaxel combined with Carboplatin has a good effect in the treatment of advanced ovarian cancer, which can significantly improve the immune status and ovarian hemodynamic parameters.